Navigation Links
TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
Date:2/25/2010

PLEASANTON, Calif., Feb. 25 /PRNewswire/ -- TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for its newest product, the Glider™ balloon catheter, for percutaneous transluminal angioplasty (PTA) of lesions in the peripheral vasculature including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.

Approximately 12 million Americans are affected by peripheral arterial disease (PAD). Those patients suffer from chronic pain, significant mobility limitations and debilitating quality of life. Left untreated, PAD can lead to a limb loss and even to death.

PAD represents a large unmet clinical need and a critical public health issue. Current balloon and stent therapies suffer from shortcomings in the challenging peripheral environment, evidenced by a low rate of acute and long term success.

"The Glider™ PTA 510K clearance is an important step towards sales of our products in the US market," said Eitan Konstantino, Ph.D., President and Chief Executive Officer of TMI. "This product complements our existing portfolio of Glider™ PTCA and Antares® stent system that are approved and sold in Europe."

An advanced and differentiated product for the PAD therapy market, Glider™ PTA catheters have shaft construction reinforced for torque transmission and an a-traumatic tapered tip configuration. Designed to be delivered through the complex peripheral anatomy to cross long and tight lesions and to restore blood flow in the vessels, Glider™ PTA catheters provide physicians a powerful new tool to treat patients with PAD.

About TriReme Medical, Inc.

Based in Pleasanton, California, TriReme Medical, Inc. (TMI) is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease.  The Company's novel balloon and stent therapies are specifically designed for large, unmet clinical needs.  

TMI can be contacted at +1 (925) 931-1300 or info@trirememedical.com.

SOURCE TriReme Medical, Inc.

Back to top
'/>"/>
SOURCE TriReme Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
2. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
3. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
4. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
5. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
6. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
7. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
8. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
9. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
10. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
11. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ... pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, ... , Dr. Olson says the decision to support the pageant in an official ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Today, ... optimize the ingestion of their medication by matching users with high quality water pipes ... compare pieces with no commitment. , Inhale was founded by two brothers, Nick and ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 ... between head and neck cancer in individuals with unhealthy oral hygiene habits. The article ... on whether they had gum disease, brushed their teeth on a daily basis, wore ...
Breaking Medicine News(10 mins):